Progress in hepatitis B prevention through universal infant vaccination--China, 1997-2006
- PMID: 17495790
Progress in hepatitis B prevention through universal infant vaccination--China, 1997-2006
Abstract
Hepatitis B virus (HBV) infection is a leading cause of illness and death in China. Approximately 60% of the population has a history of HBV infection, and 9.8% of persons in China are chronically infected with HBV and at risk for premature death from liver disease. Each year, an estimated 263,000 persons in China die from HBV-related liver cancer or cirrhosis, accounting for 37%-50% of HBV-related deaths worldwide. Because most HBV infections occur during infancy or early childhood, when HBV infection is most likely to become chronic, vaccination of infants beginning at birth is the key strategy for preventing chronic HBV infection. This report describes China's progress in increasing coverage among infants with hepatitis B vaccine (HepB) and timely administration of the HepB birth dose (i.e., within 24 hours of birth). Infant vaccination coverage with both the timely birth dose and the complete vaccine series was substantially higher among children born during 2003 than among those born during 1997; timely birth-dose coverage increased from 29.1% to 75.8%, and HepB series completion increased from 70.7% to 89.8%. Furthermore, in economically disadvantaged populations in western and middle provinces targeted by the China-Global Alliance for Vaccines and Immunization (China-GAVI) project, reported coverage with timely HepB birth dose increased from 64% in 2004 to 81% in 2006, and coverage with the complete HepB series increased from 52% in 2001 to 92% in 2006. China has established a goal to reduce chronic HBV infection among children aged <5 years to <1% by 2010. Achieving this goal will require continued commitment to increasing vaccination coverage in impoverished regions and ensuring that infants born at home are vaccinated within 24 hours of birth.
Similar articles
-
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.Int J Epidemiol. 2005 Dec;34(6):1329-39. doi: 10.1093/ije/dyi206. Epub 2005 Oct 25. Int J Epidemiol. 2005. PMID: 16249217
-
Implementation of newborn hepatitis B vaccination--worldwide, 2006.MMWR Morb Mortal Wkly Rep. 2008 Nov 21;57(46):1249-52. MMWR Morb Mortal Wkly Rep. 2008. PMID: 19023261
-
Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People's Republic of China.Am J Trop Med Hyg. 2009 Nov;81(5):869-74. doi: 10.4269/ajtmh.2009.09-0238. Am J Trop Med Hyg. 2009. PMID: 19861624
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
-
Prevention and control of hepatitis B in China.J Med Virol. 2002 Jul;67(3):447-50. doi: 10.1002/jmv.10094. J Med Virol. 2002. PMID: 12116043 Review.
Cited by
-
Time interval distribution of hepatitis B vaccine immunization among infants in China from 2017 to 2021.Hum Vaccin Immunother. 2024 Dec 31;20(1):2395087. doi: 10.1080/21645515.2024.2395087. Epub 2024 Sep 9. Hum Vaccin Immunother. 2024. PMID: 39247981 Free PMC article.
-
Analysis of hepatitis B Virus Test results among blood donors in Chongqing, China.BMC Infect Dis. 2024 Aug 23;24(1):857. doi: 10.1186/s12879-024-09753-8. BMC Infect Dis. 2024. PMID: 39179973 Free PMC article.
-
Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.Gut. 2023 Nov 24;72(12):2354-2363. doi: 10.1136/gutjnl-2023-330691. Gut. 2023. PMID: 37798085 Free PMC article.
-
Mathematical model analysis of effective intervention strategies on transmission dynamics of hepatitis B virus.Sci Rep. 2023 May 30;13(1):8737. doi: 10.1038/s41598-023-35815-z. Sci Rep. 2023. PMID: 37253760 Free PMC article.
-
Complementary Presence of HBV Humoral and T-cell Response Provides Protective Immunity after Neonatal Immunization.J Clin Transl Hepatol. 2022 Aug 28;10(4):660-668. doi: 10.14218/JCTH.2021.00272. Epub 2022 Jan 4. J Clin Transl Hepatol. 2022. PMID: 36062290 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources